A study of SHR-1826 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be advanced or metastatic (has spread) and have stopped responding to standard treatments, or there is no standard treatment available.
- You must be able to take care of yourself (ECOG score 0 or 1), meaning you are up and about for most of the day.
- You must have at least one tumor that can be measured on a scan (like a CT or MRI).
- Your major organs (heart, liver, kidneys, etc.) must be working well enough based on blood tests and your doctor's assessment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-1826, combined with other cancer treatments for people with advanced solid tumors that have not responded to prior therapy. The goal is to see if the combination is safe and effective.
This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called SHR-3276 for people with advanced cancers that haven't responded to standard treatments. It aims to see if the drug is safe and works against tumors.
This trial tests a new drug called SHR-3792 for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and how it affects the tumors.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug called SHR-4602, alone or with other cancer treatments, for people with advanced solid tumors that have HER2 protein. It may be an option if you have already tried standard therapies and your cancer is still growing.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.